Nuformix plc (LON:NFX – Get Free Report) was down 10.7% during mid-day trading on Wednesday . The company traded as low as GBX 0.18 and last traded at GBX 0.18. Approximately 3,820,803 shares changed hands during trading, a decline of 90% from the average daily volume of 37,000,402 shares. The stock had previously closed at GBX 0.21.
Nuformix Price Performance
The firm has a market cap of £4.78 million, a P/E ratio of -6.25 and a beta of 1.55. The stock has a 50 day moving average of GBX 0.18 and a 200 day moving average of GBX 0.22.
Nuformix (LON:NFX – Get Free Report) last issued its quarterly earnings results on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
- Insiders Are Selling These 3 Stocks—Should Investors Be Concerned?
- After SpaceX, Amazon Could Be The Next Best Space Stock
- 3 Stocks to Watch If the Strait of Hormuz Reopens
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
